Study With [225Ac]Ac-FL-020 in mCRPC Participants

The purpose of this study is to evaluate the safety, therapeutic effect, and pharmacokinetics of \[225Ac\]Ac-FL-020 in participants with metastatic castration-resistant prostate cancer (mCRPC).

Trial Details

NCT ID
NCT06492122
Phase
PHASE1
Sponsor
Full-Life Technologies UK Limited
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • [225Ac]Ac-FL-020
  • Blood samples for PK
  • [111In]In-FL-020
  • Blood and urine samples collection
  • SPECT/CT images
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Irvine, California, United States|33.66946,-117.82311
  • Stanford, California, United States|37.42411,-122.16608
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Charlottesville, Virginia, United States|38.02931,-78.47668

Key Eligibility Criteria

  • Histologically or cytologically confirmed metastatic CRPC.
  • Age ≥ 18 years.
  • Signed informed consent, and able and willing to comply with protocol requirements prior to any study procedures.
  • Patients must have a life expectancy \>3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →